We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » COVID-19 Skews Abbott’s Heart Failure Monitor Trial Results
Abbott Laboratories’ CardioMEMS implantable heart failure monitor missed the primary endpoint in an expanded patient population, but the company said that COVID-19 may have skewed the results.
To View This Article:
Login
Subscribe To International Devices & Diagnostics Monitor